Ekso Bionics: commercial relationships that shape revenue and risk

Ekso Bionics designs, sells and rents powered exoskeletons for medical and industrial customers and monetizes through a mix of device sales, rental/subscription contracts and channel distribution agreements, with Medicare reimbursement and strategic distributors amplifying reach into individual and institutional markets. This revenue mix is concentrated in healthcare enterprise sales and an expanding personal-use channel that leverages Durable Medical Equipment (DME) resellers and exclusive CRT distributors to convert reimbursement into end-customer purchases. For investors, the business is defined by recurring recognition on multi‑period subscriptions, a small number of material counterparties, and channel-led commercialization that accelerates adoption but concentrates counterparty risk.
Explore Ekso customer intelligence on NullExposure

Key takeaways

Monetization: product sales + subscription/rental contracts (24‑month recognition cited) and DME resale under Medicare reimbursement.
Concentration: one customer accounted for ≥10% of revenue in 2023–2024, signaling meaningful counterparty concentration.
Distribution strategy: growing reliance on exclusive and category distributors (CRT, O&P, DMEs) and market-access partners to scale commercial adoption.

How relationships are being used in the field today

Ekso’s public disclosures and media coverage enumerate partnerships across clinical, rehabilitation, construction and industrial segments. The roster mixes exclusive distributor arrangements, commercial pilots and institutional purchases that together define go‑to‑market traction and risk.

National Seating & Mobility — exclusive CRT distributor in the U.S.

Ekso named National Seating & Mobility (NSM) as its exclusive Ekso Indego Personal device distributor within the complex rehabilitation technology (CRT) market in the U.S., and reported receiving NSM’s first order in Q2 2025. This is a strategic, exclusive-channel play to access Medicare‑eligible individual customers through a leading CRT reseller. (Ekso 2025 Q1 and 2025 Q2 earnings calls; QuiverQuant press release, FY2025.)

Bionic P&O — first prosthetic & orthotic (O&P) distributor

Ekso appointed Bionic P&O as its first O&P distributor, a national prosthetic and orthotic provider intended to extend Ekso Indego reach into O&P clinics and specialist outlets. The company announced Bionic P&O in both Q1 and Q2 2025 investor calls. (Ekso 2025 Q1 and 2025 Q2 earnings calls.)

PRIA Healthcare — market access and commercialization services

Ekso engaged PRIA Healthcare to support market access; management highlighted PRIA’s role in commercialization and noted the firm’s track record across more than 300 medical devices. This is a deliberate move to strengthen reimbursement workflows and payer engagement. (Ekso 2025 Q1 and Q2 earnings calls.)

Post Acute Medical LLC — institutional expansion of EksoNR

Post Acute Medical expanded its deployed base by acquiring three additional EksoNR units to increase exoskeleton‑assisted rehabilitation across seven facilities, illustrating adoption in long‑term acute care (LTAC) hospital systems. This transaction reflects product demand in inpatient rehab settings. (ptproductsonline.com, FY2020.)

Kindred Healthcare — pilot and program deployments in LTAC hospitals

Kindred Healthcare has collaborated with Ekso on testing and deploying EksoNR systems across multiple long‑term acute care hospitals, with coverage in 2020–2021 press; management has previously referenced the Kindred relationship when discussing clinical validation and commercial momentum in LTAC environments. (ExoskeletonReport, FY2020; Robotics and Automation News, FY2021.)

Ford Motor Co — industrial partnership for worker support

Ekso partnered with Ford on exoskeleton development to support industrial workers, a non‑medical application demonstrating product adaptability to ergonomic and industrial use cases; details on commercial terms were not disclosed in the 2017 coverage. (Interaksyon / PhilStar report, FY2017.)

EGM Builders — first adopter of EVO in construction

EGM Builders was announced as the first customer to adopt Ekso’s EVO units in construction, signaling entry into contractor workflows where exoskeletons reduce fatigue and injury risk for skilled tradespeople. This represents a vertical pilot that validates industrial product-market fit. (ForConstructionPros, FY2020.)

MediTouch — exclusive U.S. distributor for BalanceTutor

Ekso entered an exclusivity agreement with MediTouch to distribute the BalanceTutor rehabilitation system across the United States, strengthening the company’s footprint in balance and gait rehabilitation devices for clinics and rehab centers. (StocksToTrade news release, FY2025.)

What the relationship set says about Ekso’s operating model

Ekso’s relationship mix delivers four clear operating-model signals:

Contracting posture — subscription and resale-led recognition. Ekso recognizes revenue from medical device subscriptions evenly over contract terms (commonly 24 months), which supports recurring cash flow but ties revenue recognition to multi‑period contracts rather than single upfront receipts. Evidence also shows the company uses DME resellers for Medicare‑driven individual sales, embedding third‑party reimbursement processes into its go‑to‑market. (Company disclosures on revenue recognition and Medicare reimbursement.)
Counterparty concentration and materiality. Management reports one customer representing ≥10% of revenue for 2023–2024, indicating meaningful concentration that elevates single‑counterparty risk even as exclusive distributor agreements aim to broaden access.
Criticality and channel dependence. Devices are clinically critical for rehabilitation workflows; Ekso is therefore highly dependent on channel partners (exclusive CRT distributors, O&P distributors, DMEs) and on market‑access specialists to unlock reimbursement and end‑user purchasing.
Maturity and segmentation. Ekso operates as a single healthcare segment with enterprise neurorehabilitation as the revenue core while expanding into personal mobility and industrial verticals; the company is in a growth commercialization phase where distributor scalability is a strategic priority.

Risk implications and investor considerations

Commercial concentration amplifies the impact of distributor performance; loss or underperformance by an exclusive partner could materially affect sales.
Reimbursement dependency creates timing and cash‑flow risk; however, CMS payment levels (approx. $91,000 for Ekso Indego Personal effective April 2024) materially improve unit economics for end customers and support resale volumes through DMEs.
Channel complexity requires robust market‑access capability — the PRIA engagement is a direct response to this requirement and is a positive operational hedge.

For a deeper, transaction‑level view of Ekso’s commercial relationships and to monitor changes in distributor agreements and deployment announcements, visit NullExposure’s customer intelligence hub: https://nullexposure.com/

Final read: why these relationships matter now

Ekso’s near‑term growth depends on converting Medicare reimbursement and exclusive distributor relationships into repeatable unit sales and subscription revenue. The company’s commercial strategy is clear: leverage high‑profile institutional wins to validate clinical benefit while scaling through exclusive CRT, O&P and DME channels to reach individuals. That combination improves revenue quality via subscription recognition while concentrating counterparty risk — the central tradeoff investors should price into valuation models.

Stay updated on Ekso customer activity and strategic partner developments at NullExposure: https://nullexposure.com/ — analysts and operators will find the customer relationship timelines and sourcing useful for modeling commercial ramp and counterparty risk.

EKSO customer relationships